Twitter Beğeni Hilesi

Our summary and insights of “mHSPC 2023” - check it out Neeraj Agarwal, MD, FASCO Christopher Sweeney, MBBS Nicolas Sayegh, MD ASCO

Good morning #ASCO23 ! Presenting our work in the Prostate poster session this morning - serial CTC profiling tracking response in the LuPARP trial. Peter Mac Research Prostate Cancer Foundation Trial results to be presented in Oral Abstracts A/Prof. Shahneen Sandhu

Anis Hamid explains these data. Should BRCA patients have chemo intensification? #ASCO2023

#ASCO23 ASCO Karim Fizazi presents HRR-def cohort from Talapro-2 (Enza + Tala vs PBO + Tala) in mCRPC. Sig ⬆️ in rPFS (HR 0.45) with encouraging early OS signal (HR 0.69) - BRCA1/2 (HR 0.61) & non-BRCA (HR 0.66). These pivotal data reinforce role of NHA + PARP in HRR-def pts.

Check out our new study in Science Magazine, where we take on a 100-year-old debate: what’s the role of aneuploidy in cancer? We discovered that genetically removing extra chromosomes blocks cancer growth - a phenomenon we call “aneuploidy addiction”. science.org/doi/10.1126/sc…

Kudos Alex Wyatt what a great reflection on cross-disciplinary (scientist-clinician, clinician-scientist) learning and respect inspiring cancer research #ANZUP23

Nice collaboration with Francesca Khani, MD Will Hooper Olivier Elemento Nicolas Robine and many others - Evolution of structural rearrangements in prostate cancer intracranial metastases npj Journals Dana-Farber NY Genome Center Weill Cornell Medicine nature.com/articles/s4169…

#Tweetorial: Data from Drake Lab and others shows CSPC is immunologically different and not an ‘immune desert’ like CRPC. We interrogated CSPC metastases with single-cell RNA-seq (scRNA-seq), VIPER, and IF before and after tx w/ ADT +/- aPD-1 in a Phase 2 study. /1

Does the evolutionary history of a cancer predict outcome? In our pre-print, we introduce a new method to measure a cancer’s past using bulk methylation data. In chronic lymphocytic leukaemia (CLL), these inferred histories are highly prognostic! (1/9) doi.org/10.1101/2023.1…

Our latest study with Piet Ost, of whole prostates, lymph nodes, and ctDNA at initial diagnosis in de novo metastatic prostate cancer (distant mets) is out in Nature Cancer: rdcu.be/du8Tu. 1/n thread 👇

ANZUP celebrates Margaret McJannett as she "retires" (yeah right I suspect there won't be much putting up of feet), and welcomes our new CEO Samantha Oakes

Capping off a month on staff Memorial Sloan Kettering Cancer Center GU Onc. Much exciting work to be done and a fantastic, welcoming team all around Jonathan Rosenberg MD Michael Morris Dr. Darren Feldman et al. Thankful to mentors + collaborators along the way Christopher Sweeney, MBBS Dana-Farber Lank Center for Genitourinary Oncology Ian Davis ANZUP

TP53: - Discovered 45 years ago, most cited gene all time - No therapies - 500 million people currently living will die of TP53 mutant cancers without new therapies Our Preprint: - A general strategy for TP53 missense mutant cancers (majority) with prototype small molecules

Official now 🤓 Beatriz

Attention all postdocs - this is an incredible opportunity with a wonderful mentor to help advance great science and your career!!!! Uromigos Eli Van Allen Anis Hamid

Great to finally meet all in person! Here we are: ESMO - Eur. Oncology Translational Research Faculty, chaired by Turajlic Lab @ The Crick. #ESMO24 🔬🧪🧑‍🔬 Watch the space for exciting projects ahead! 💡If you have any burning ideas/suggestions re: #TranslationalResearch - feel free to reach out too!

📢 Just published in JCO! What is the optimal chemotherapy for oligodendroglioma patients? Our study using data from the national prospective cohort POLA found better PFS and OS outcomes with first-line RT/PCV compared to RT/TMZ ascopubs.org/doi/10.1200/JC…

Great pod ⁦GU Cast | Urology podcast!⁩ ! thanks for sharing ⁦Christopher Sweeney, MBBS⁩ ⁦Ian Davis⁩ thanks for doing ⁦ANZUP⁩ looking fwd to further correlatives analyses ⁦Anis Hamid Lisa Horvath podcasts.apple.com/us/podcast/gu-…